
Please try another search
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of America, and internationally. It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which is correlated with cell proliferation. It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Jesper Soderqvist | 59 | 2013 | Independent Director |
Anders Rylander | 55 | 2010 | President, CEO & Director |
Maria Birgitte Holmlund | 69 | 2016 | Independent Director |
Lars Erik Holmqvist | 66 | 2018 | Independent Chairman of the Board |
Marie-Louise Helena Fjallskog | 61 | 2020 | Independent Director |
Annika Carlsson Berg | 62 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review